Ad
related to: does keytruda treat kidney cancer
Search results
Results from the WOW.Com Content Network
Merck (MRK) and partner Eisai report positive top-line data from the phase III study evaluating Keytruda plus the latter's Lenvima for first-line treatment of patients with kidney cancer.
Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody, more specifically a PD-1 inhibitor, used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer.
Following EU nod, Merck's (MRK) Keytruda is now approved as an adjuvant therapy for renal cell carcinoma in certain adult patients who are at an increased risk of recurrence, following nephrectomy.
Merck (MRK) is developing a Keytruda monotherapy regimen for adjuvant treatment of renal cell carcinoma patients.
It was approved in 2014. Nivolumab is approved to treat melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, and Hodgkin's lymphoma. [16] Pembrolizumab (brand name Keytruda) is another PD-1 inhibitor that was approved by the FDA in 2014 and was the second checkpoint inhibitor approved in the United States. [17]
It was approved in 2014. Nivolumab is approved to treat melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, and Hodgkin's lymphoma. [160] A 2016 clinical trial for non-small cell lung cancer failed to meet its primary endpoint for treatment in the first-line setting, but is FDA-approved in subsequent lines of therapy. [161]
Merck's (MRK) label expansion application for Keytruda in combination with Pfizer's Inlyta for the first-line treatment of renal cell carcinoma gets approval in Europe.
The opinion is based on Phase 3 KEYNOTE-564 trial data, in which Keytruda reduced the risk of diseas EMA's CHMP Backs Approval For Merck's Keytruda In Adjuvant Setting For Kidney Cancer Skip to ...
Ad
related to: does keytruda treat kidney cancer